Abstract Purpose of Review Heart failure (HF) is one of the leading causes of cardiac
morbidity and mortality around the world. Our evolving understanding of the cellular and …

Heart failure (HF) represents a significant global health challenge, characterized by high
morbidity and mortality rates, and imposes considerable burdens on healthcare systems and …

The recent explosion of scientific knowledge and technological progress has led to the
discovery of a large array of circulating molecules commonly referred to as biomarkers …

Biomarker testing in patients with heart failure (HF) is rapidly expanding. With high-quality
research indicating its diagnostic and prognostic capabilities, biomarkers are excellent …

Heart failure (HF) is a complex syndrome with an enormous societal burden in terms of cost,
morbidity, and mortality. Natriuretic peptide testing is now widely used to support diagnosis …

The proliferation of cardiac‐related biomarkers and advocacy for their use has often come
without adequate discussion of limitations in the interpretation of values and their best use in …

Opinion statement Investigation of the complex biochemical pathways that underlie heart
failure (HF) has led to the recognition of multiple molecular markers that may help to …

Understanding of chronic heart failure (HF) has progressed from the concept of a purely
hemodynamic disorder to that of a syndrome that results from dysfunction in interconnected …

The approval of new heart failure (HF) therapies has slowed over the past two decades in
part due to the high costs of conducting large randomized clinical trials that are needed to …

Current clinical recommendations provided by the 2016 European Society of Cardiology
(ESC) and 2017 American College of Cardiology (ACC)/American Heart Association …